/PRNewswire/ Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of.
Ginkgo Bioworks (DNA) Acquires Modulus Therapeutics Cell Therapy Assets streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ginkgo Bioworks Acquires Modulus Therapeutics Cell Therapy Assets To Strengthen Next-Gen CAR Designs menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Anna Marie Wagner: Good afternoon. I m Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. I m joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023
Recent acquisition of the adeno-associated virus capsid engineering platform assets of StrideBio is advancing Ginkgo s. | May 10, 2023